Literature DB >> 26295486

The emerging role of multiple antiphospholipid antibodies positivity in patients with antiphospholipid syndrome.

Ricardo Forastiero1, Marta Martinuzzo2.   

Abstract

Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by clinical symptoms of vascular thrombosis and/or pregnancy morbidity in the presence of autoimmune antiphospholipid antibodies (aPL). Current laboratory APS criteria include the presence of at least one of the three relevant aPL: lupus anticoagulant, anticardiolipin antibodies and anti-β2 glycoprotein I antibodies. Therefore, patients could have a single aPL pattern or combinations of aPL. Evidence arising from clinical experience indicates that patients having the highest aPL titer and simultaneous aPL detected by different tests have a worse prognosis and a higher probability of recurrence of the APS clinical features. In recent years, an emerging role of multiple aPL positivity in the identification of high-risk patients with aPL/APS is evident. This paper will review the current knowledge on the clinical relevance of having single or multiple aPL positivity.

Entities:  

Keywords:  antiphospholipid antibodies; antiphospholipid syndrome; arterial thrombosis; pregnancy morbidity; venous thrombosis

Mesh:

Substances:

Year:  2015        PMID: 26295486     DOI: 10.1586/1744666X.2015.1080121

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  2 in total

Review 1.  Obstetric Anti-phospholipid Syndrome: State of the Art.

Authors:  Maria Chiara Gerardi; Melissa Alexandre Fernandes; Angela Tincani; Laura Andreoli
Journal:  Curr Rheumatol Rep       Date:  2018-08-13       Impact factor: 4.592

2.  Detection of multiple annexin autoantibodies in a patient with recurrent miscarriages, fulminant stroke and seronegative antiphospholipid syndrome.

Authors:  Philipp Scholz; Markus Auler; Bent Brachvogel; Thomas Benzing; Peter Mallman; Thomas Streichert; Andreas R Klatt
Journal:  Biochem Med (Zagreb)       Date:  2016       Impact factor: 2.313

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.